Ifosfamide combined with toremifene in the treatment of non-small cell lung cancer.
The efficacy and safety of toremifene-ifosfamide as a first-line chemotherapy in non-small cell lung cancer were assessed. Sixteen patients were treated with oral toremifene (420 mg on days 1-4 and 240 mg on day 5) followed by ifosfamide infusion 5 g/m2 on day 5 every 3 weeks 1-6 times. Toremifene at the doses used did not enhance the effect or toxicity of ifosfamide in previously untreated non-small cell lung cancer patients.
Salomaa
E R
ER
Turku University Hospital, Department of Pulmonary Diseases and Clinical Allergology, Preitilä, Finland.
Liippo
K
K
Ellmen
J
J
Komi
J
J
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004334:Drug Administration Schedule; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017312:Toremifene / Q000008:administration & dosage; D016896:Treatment Outcome
D017312:Toremifene; D007069:Ifosfamide